Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 35

Do antipsychotic drugs block insulin action in the brain?

Official title: Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?

Run by Centre for Addiction and Mental Health · NCT07109245 · Data updated 2026-11-12

This project will test whether haloperidol blocks insulin action in the brain of healthy adults aged 18–35.

More Cognition trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 35 Years
SexAll
Enrollment35 (estimated)
SponsorCentre for Addiction and Mental Health
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedDecember 11, 2025
Main results expectedAugust 2028
Study endsDecember 2028
Registry record updatedApril 2, 2026
Trial IDNCT07109245 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults aged 18–35 with BMI 18.5–24.9, normal glucose metabolism and insulin sensitivity, no psychiatric history, and ability to consent are ideal candidates.

Probably not a fit

People with psychiatric disorders, diabetes or prediabetes, impaired insulin sensitivity, a family history of diabetes, or outside the specified age/BMI ranges are not eligible and are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 interventional study enrolls healthy 18–35-year-old adults with normal BMI and no psychiatric or metabolic disorders. Participants receive pharmacologic challenges with haloperidol or placebo and with insulin lispro or saline while investigators measure brain responses and cognition using MRI and cognitive tests. The design compares brain insulin signaling and cognitive effects after antipsychotic versus placebo exposure to see if haloperidol interferes with insulin action in the brain. Strict metabolic and psychiatric exclusion criteria are used to isolate drug effects in metabolically healthy volunteers.

Why it matters

Potential benefit: If successful, the results could clarify whether antipsychotics impair brain insulin signaling and inform strategies to reduce metabolic and cognitive side effects in patients on these drugs.

How similar studies have gone: Prior research has linked antipsychotics to systemic metabolic side effects and altered cognition, but direct effects of haloperidol on brain insulin signaling remain relatively novel and not well-established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Must be deemed to have the capacity to provide informed consent
2. Must sign and date the informed consent form
3. Stated willingness to comply with all study procedures;
4. Age: 18-35
5. Body Mass Index (BMI) 18.5-24.9 kg/m2
6. Both sexes

Exclusion Criteria:

1. History of psychiatric illness, including any substance use (screened using the Mini International Neuropsychiatric Interview (MINI))
2. Pre-diabetes or diabetes (fasting glucose ≥6.0 mmol/L, HbA1c\>6% or use of anti-diabetic drug),
3. Evidence of impaired insulin sensitivity, assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≥2.5
4. Family history of diabetes in a first degree relative (parent or sibling)
5. Use of weight reducing agents
6. History of kidney or liver disease
7. History of cell blood disorders
8. Irregular menstrual cycles (e.g., menstruation occurs less than 21 days or more than 35 days apart, or not having menstruated for three months (or 90 days), or conditions such as endometriosis or polycystic ovary syndrome (PCOS) or prior surgical interventions such as a hysterectomy or oophorectomy)
9. Current use of hormonal birth control (e.g., pill, patch, hormonal intrauterine device \[IUD\], ring). Participants must have had at least 2 regular menstrual cycles following the discontinuation of hormonal birth control \[50\]
10. Current use of progesterone, estrogen, testosterone, or fertility treatment.
11. Pregnant, gave birth in the last year, or breastfeeding. Participants must have at least 3 regular menstrual cycles post-breastfeeding before beginning the study.
12. Major medical or surgical event within the last 6 months
13. Contraindications for MRI, including metal implants, pacemakers, cochlear implants, claustrophobia, weight \>250 lbs
14. Any contraindications to the investigational products as listed in the product monographs including known hypersensitivity to the drug or the excipients of the product (note: enzymatic lactose intolerance is NOT exclusionary),
15. Any medications that increases risk of hypoglycemia or could contribute to hyperglycemia
16. Any medical conditions that constitute as a warning/precaution for haloperidol, lorazepam, benztropine, or insulin.
17. Use of any of the prohibited medications listed in the product monograph of haloperidol, lorazepam, benztropine, or insulin (Pheochromocytoma, barbiturates, and narcotics are exclusionary, any use of painkillers and antihistamines must be reviewed by PI but are not exclusionary

Where it's running

  • Centre for Addiction and Mental Health
    Toronto, Ontario, Canada
    Recruiting

Study contacts

  • Principal investigator: Mahavir Agarwal, MBBS, MD, PhD — Centre for Addiction and Mental Health
  • Study coordinator: Mahavir Agarwal, MBBS, MD, PhD
  • Email: mahavir.agarwal@camh.ca
  • Phone: 416-535-8501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.